ELSEVIER Journal of Affective Disorders Author index V. and Stewart, JW Faraone, SV see Biederman, J. (47) 113 Social functioning and residual symptomatology among out Feighner, J.P. Entsuah A.R ind McPherson, M.K patients who responded to treatment and recovered from major Efficacy of once-daily venlafaxine extended release (XR) for epression (4 207 symptoms of anxiety in depressed outpatients (47) 555 Akiskal H.S see Perugi, G. (47) Fujikawa, T., see Yanai, | (47) 25 Aniskal H.S see Placidi, G.I Alexander, PE see Uhlenhuth Garcia-Espana, F., see Amsterdam, J.D. (47) Ambrumo see Polyako' }) 159 Gayant, ( see Loas, G. (47 Sl Garcia-Espana, F. and Rybakowski, J Gervasi, R see Placidi G.F 47) n patients w ith iffective illness Guelfi J.D., see Loas, G (47) 81 Guertin, J.E., see Enns M.W. (47) 195 Hadzi-Pavlovic, D see Parker, G. (47) 131 see Perugi, G. (47) 11 Hale Ill, WW Jansen JHC Bouhuys, A.L. and van den Mick, I and Faraone, S.\ Hoofdakker R.H nN att ention deficit hyperactivity disorder (ADHD The judgment of facial expressions by depressed patients, their rue’ depression or demoralization? (4 1133 partners and controls (47) 63 Bo Mortetr se see Kessing, LV. (47 3] Hawley, CJ Pattinson H.A., Quick, S.J Echlin, D Smith, V B o Mort ensen see Kessing, LV. (47) 41 McPhee, S. and Sivakumaran, T Bolwig Kessing, L.V 1) 31 A protocol for the pharmacologic treatment of major depres Bolwig Kessing, LV sion A field test of a potential prototype (4 ) 87 Bouhuys Heiligenstein, J.H see Hylan, T.R. (47) 71 B rescn Ho, T.P see Yip P.S.I 47) 141 Horiguchi, J., see Yanai, | 7) 25 Horton, R.W., see Lawrence K.M. (47 105 B.S Hylan, T.R Crown W.H Meneades, | Heiligenstein, J.H., see Melfi, C.A Croghan TW. and Buesching D.P. TW Tricyclic intidepressant and selective serotonin reuptake in ympton M.R., see hibitors antidepressant selection and health care costs in the Cr own W.H., see Hylan naturalistic setting: a multivariate analysis (47) 71 De ikin, B., see Strickland P. (47 Jansen, J.H.A see Hale Ill WW (47) 63 De mpsey G.M.., see Uhlenhuth Joffe, R.T see Levitt, A.J (47) 169 Dinan r.G., see Scott, LV Jones, W see Uhlenhuth, E.H (47) 183 Duggan, ¢ Sham, P., Minne, C , Lee, A. and Murray, R Does the method of data collection affect the reporting of Kanagasundaram, M., see Lawrence, K.M depression in the relatives of depressed probands? (47) 151 Katona, C.L.E., see Lawrence, K.M. (47) Kemper, B., see Kuhs, H. (47) 97 Ect lin, D., see Hawley, C.J. (47) 8 Kessing, L.V., Bo Mortensen, P. and Bolwig, T.G Enns, M.W Cox, B.J., Parker J.D.A. and Guertin, J.t Clinical definitions of sensitisation in affective disorder a case Confirmatory factor analysis of the Beck Anxiety and Depres register study of prevalence and prediction (47) 31 sion Inventories in patients with major depression (47) 195 Kessing, LV., Bo Mortensen, P. and Bolwig, T.B Entsuah, A.R see F eighner 55 97)00186 d Lerner, V lepression versus and Kueneman, K npatient suicide (4 ind Deaki hronic tati G.M Jone Simonett Akiskal, H.S inxious temperament rd a rapprochement of etta \.. Gervasi, R.,. Maremmani lepr ession and silent <« A\Kiskal ip. PS. Chao \ The semi-structured affective temperament interview \ re xamination of iriation in suicides in Australia PS-I). Reliability and psychometric properties 1-26 and New Ze and id students (4 Journal of Affective Disorders Subject index ADHD; Ma Comorbidity; Remission: Persistence Combined pharmacotherapy and sleep deprivation; Major 47, 113 depressive episode; Partial sleep deprivation; Repeated sleep deprivartion; Sleep deprivation interval 47, 97 Adjustment reaction; Major depression; Suicidal attempt 47, 159 Comorbidity; Major Depression; ADHD; Remission; Persistence Affective disorder; C: Sensitisation; Course 47, 31 47, 113 Affective disorder; , > Sensitisation; Alcohol; De Compliance; Depression; Lithium; Lofepramine; Paroxetine mentia: Suicide 47, 41 Protocol 47, 87 Affective disorders; Viral infections: Ant Psychotropic Confirmatory factor analysis; Depression; Anxiety; Measure Lithium 47, ment 47, 195 Affective temperaments; Cyclothymic; Depressive; Hyper Cortisol; Chronic fatigue syndrome; Depression; Saliva 47, 191 thymic; Irritable 47, Course; Affective disorder; Case register; Sensitisation 47, 31 Agoraphobia; P>a nic disorder; Phobic-anxious temperament; Hy Cyclothymic; Affective temperaments; Depressive; Hyperthymic; rsensitivity to separation; Prodromal symptoms 47, 11 Irritable 47, | ise register: Sensitisation: De Dementia; Depression; Cerebral infarction; Magnetic resonance imaging 47, 25 Antidepressant drugs; Suicide; Depression H ]imipramine Dementia; Affective disorder; Case register; Sensitisation sites; Post-mortem brain tissue; Frontal cortex; Putamen cohol; Suicide 47, 41 1 47, 105 Dependency; Depression; Factor analysis 47, 81 Antidepressants; Depr Dysthymia; Double depression 47, Depression; Dementia; Cerebral infarction; Magnetic resonance VY imaging 47, 25 Anti-viral; Viral infections; Psychotropic drugs; Lithium, Affec Depression; Chronic fatigue syndrome (CFS); Urinary free tive disorders 47, 177 cortisol (UFC); Hypothalamic-pituitary-adrenal (HPA) axis 47, 49 Anxiety; Major depression; Venlafaxine; Extended-release 47, 55 Depression; Facial expression; Face; Judgment of emotions Depression severity 47, 63 Anxiety; Depression; Measurement; Confirmatory factor analysis 47, 195 Depression; Health care costs; Selective serotonin reuptake inhibitors; Tricyclic antidepressants 47, 71 Anxiety disorders; Negative placebo respio nse; Somatization Extended release alprazolam 47, 183 Depression; Dependency; Factor analysis 47, 81 Case register; Affective disorder; Sensitisation; Course 47, 31 Depression; Compliance; Lithium; Lofepramine; Paroxetine; Protocol 47, 87 Case register; Affective disorder; Sensitisation; Alcohol; De Depression; Suicide; | H]imipramine binding sites; Post-mortem mentia: Suicide 47, 41 brain tissue; Antidepressant drugs; Frontal cortex; Putamen; Cerebral infarction; Depression; Dementia; Magnetic resonance Substantia nigra 47, 105 maging 47, 25 Depression; Mood disorder; Personality; Melancholic and non Chronic fatigue syndrome (CFS); Depression; Urinary free melancholic depression; Sub-typing 47, 131 cortisol (UFC); Hypothalamic-pituitary-adrenal (HPA) axis 47, 49 Depression; Dysthymia; Antidepressants; Double depression 47, Chronic fatigue syndrome; Depression; Cortisol; Saliva 47, 191 169 SO165 327 7)00187-0 Depression; Chronic fatigue Lofepramine; Compliance; Depression; Lithium; Paroxetine; Protocol 47, 87 Depression; Anxiety; Measuren 47, 195 Magnetic resonance imaging; Depression; Dementia; Cerebral Depression severity; Depr infarction 47, 25 en f emotions 47, 63 Major depression; Anxiety; Venlaf: xtended-release 47, 55 Depressive; Aff yclothymic; Hyperthymi Major Depression; ADHD; Comorbidity; Remission; Persistence Irritable 47, Double depression; Depression, Dys Antidepressants 47, Major depression; Genetics; Family studies 47, 15 69 Major depression; Adjustment reaction; Suicidal attempt 47, 159 Dysthymia; | Antidepressants; Double depression 47, Major depression; Recovery; Normality 47, 207 Extended release alprazolam; Anxiety disorders; Negative Major depressive episode; Partial sleep deprivation; Repeated wcebo response: Somatization 47, 183 sleep deprivartion; Combined pharmacotherapy and sleep depriva tion; Sleep deprivation interval 47, 97 Extended-release; Major depression; Anxiety; Venlafaxine 47, 55 Measurement; Depression; Anxiety; Confirmatory factor analysis f emotions 47. 195 erity 47, 63 Melancholic and non-melancholic depression; Mood disorder; Facial expression; Depression Depres Depression; Personality; Sub-typing 47, 131 Mood cycling; Suicide; Mood disorders; Inpatients 47, 123 Factor analysis; Depression; Dependency 47, 81 Mood disorder; Depression; Personality; Melancholic and non Family studies; Major Genetics 47, 151 melancholic depression; Sub-typing 47, 131 Frontal cortex; Suici ssion H]imipramine bindin tes; Post-morten Antidepressant drugs; Putamen Mood disorders; Suicide; Mood cycling; Inpatients 47, 123 47, 105 Negative placebo response; Anxiety disorders; Somatizatior Genetics; Majo *Dressior umily studies 47, 151 Extended release alrp razolam 47, 183 Harmonic analysis; Seasonal variation; Suicides Normality; Major depression; Recovery 47, 20 Health care costs; Selective serotonin reuptake inhibitors Panic disorder; Agoraphobia; Phobic-anxious temperament; Hy ants; Depression 47, 71 persensitivity to separation; Prodromal symptoms 47, 11 Hypersensitivity to separation; Pan A goraphobi: Paroxetine; Complianc« Depres ion Lithium I ofepramine PI t inxious temperament; Prodromal symptoms 47, 11 Protocol 47, 8 Hyperthymic; Affective t eraments; Cyclothymic; Depress Partial sleep deprivation; Major depressive episode; Repeated Irritable 47, sleep deprivartion; Combined pharmacotherapy and sleep depriva tion; Sleep deprivation interval 47, 97 Hypothalamic-pituitary-adrenal (HPA) axis; Chronic fatigue yndrome (CFS); Depression; Urinary free cortiso! (UFC) 47, 49 Persistence; Major Depression, ADHD; Comorbidity; Remissior | Hjimipramine binding sites; Suicide; Depression; Post-morten ue; Antidepressant drug Frontal cortex; Putamen Personality; Mood disorder, Depression; Melancholic and non melancholic depression; Sub-typing 47, 131 Inpatients; Suicide; Mood disorders; Mood cycling Phobic-anxious temperament; Panic disorder, Agoraphobia Irritable; temperaments; Cyclothymic Depressive Hypersensitivity to separation; Prodromal symptoms 47, 11 Hyperthymic 47, Post-mortem brain tissue; Suicide; Depression; { H]imipramine Judgment of emotions; Depression; Facial expression binding sites; Antidepressant drugs; Frontal cortex; Putamen Dept n severity 47, 63 Substantia nigra 47, 105 Lithium; Compliance: Depres Lofepramine; Paroxetine Prodromal symptoms; Panic disorder, Agoraphobia; Phobic inxious temperament; Hypersensitivity to separation 47, 11 Lithium; Viral infections; Ant Psychotropic drugs Protocol; Compliance; Depression; Lithium; Lofepramine; Parox t lisord4e7,r s17 7 etine 47, 87 Subject index Psychotropic drugs; Viral infections; Anti-viral; Lithium; Affec Extended release alprazolam 47, 183 tive disorders 47, 177 Substantia nigra; Suicide; Depression; [| H]imipramine binding Putamen; Suicide; Depression H]jimipramine binding sites sites; Post-mortem brain tissue; Antidepressant drugs; Frontal Post-mortem brain tissue; Antidepressant drugs; Frontal cortex cortex; Putamen 47, 105 Substantia nigra 47, 105 Sub-typing; Mood disorder; Depression; Personality; Melancholic Recovery; Major depression; Normality 47, 20 and non-melancholic depression 47, 131 Remission; Major Depression, ADHD; Comorbidity; Persistence Suicidal attempt; Major depression; Adjustment reaction 47, 159 47, 113 Suicide; Affective disorder; Case register; Sensitisation; Alcohol Repeated sleep deprivartion; Major depressive episode; Partial Dementia 47, 41 sleep deprivation; Combined pharmacotherapy and sleep depriva Suicide; Depression; [ H]imipramine binding sites; Post-mortem tion; Sleep deprivation interval 47, 97 brain tissue; Antidepressant drugs; Frontal cortex; Putamen; Saliva; Chronic fatigue syndrome; Depression; Cortisol 47, 191 Substantia nigra 47, 105 Seasonal variation; Harmonic analysis; Suicides 47, 141 Suicide; Mood disorders; Mood cycling; Inpatients 47, 123 Selective serotonin reuptake inhibitors; Health care costs Suicides; Harmonic analysis; Seasonal variation 47, 14] Tricyclic antidepressants; Depression 47, 71 Tricyclic antidepressants; Health care costs; Selective serotonin Sensitisation; Affective disorder; Case register; Course 47, reuptake inhibitors; Depression 47, 71 Sensitisation; Affective disorder; Case register; Alcohol; De Urinary free cortisol (UFC); Chronic fatigue syndrome (CFS); mentia; Suicide 4 Depression; Hypothalamic-pituitary-adrenal (HPA) axis 47, 49 Sleep deprivation interval; Major depressive episode; Partial Venlafaxine; Major depression; Anxiety; Extended-release 47, 55 sleep deprivation; Repeated sleep deprivartion, Combined phar Viral infections; Anti-viral; Psychotropic drugs; Lithium; Affec macotherapy and sleep deprivation 47, 97 tive disorders 47, 177 Somatization; Anxiety disorders; Negative placebo response